Clinical study on the efficacy and safety of telbivudine for interrupting mother-to-child transmission of hepatitis B virus (HBV) in pregnant women

Trial Profile

Clinical study on the efficacy and safety of telbivudine for interrupting mother-to-child transmission of hepatitis B virus (HBV) in pregnant women

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2016

At a glance

  • Drugs Telbivudine (Primary) ; Hepatitis B immune globulin
  • Indications Hepatitis B
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 25 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top